Immunovant Analyst Price Targets - Benzinga

Immunovant Inc

IMVTNASDAQ

Trade with Public

Trade with Public

$41.20

-2.62-5.98%

At close: Aug 27, 5:00 PM EST

$41.87

-1.95-4.45%

Pre-Market: 7:11 AM EST

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Immunovant Analyst Price Targets

Wall Street analyst price targets and consensus rating for Immunovant (IMVT).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

12Buy

3Hold

Consensus RatingBuy# Analysts15Avg. Consensus PT$43Upside to Avg. PT+3.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 4, 2026	JP Morgan	Brian Cheng	PT Raise	Overweight	$47→$50
Jun 30, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$57→$61
May 26, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$44→$62
May 22, 2026	Truist Securities	Danielle Brill	PT Raise	Hold	$23→$30
May 21, 2026	B of A Securities	Jason Gerberry	PT Raise	Buy	$32→$43
May 21, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$35→$40
Apr 15, 2026	Goldman Sachs	Corinne Johnson	PT Raise	Neutral	$29→$32
Feb 10, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$35
Feb 9, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$41→$44
Jan 8, 2026	Truist Securities	Danielle Brill	PT Raise	Hold	$16→$22
Jan 6, 2026	Wolfe Research	Andy Chen	Upgrade	Peer Perform→Outperform	$50
Dec 15, 2025	Goldman Sachs	Corinne Johnson	PT Raise	Neutral	$18→$28
Oct 14, 2025	Truist Securities	Danielle Brill	Initiate	Hold	$16
Sep 30, 2025	JP Morgan	Brian Cheng	PT Cut	Overweight	$37→$33
Sep 4, 2025	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$35
Aug 12, 2025	JP Morgan	Brian Cheng	PT Cut	Overweight	$40→$37
Aug 12, 2025	B of A Securities	Jason Gerberry	PT Cut	Buy	$33→$30
Jul 28, 2025	UBS	Ashwani Verma	PT Raise	Neutral	$17→$18
Apr 22, 2025	UBS	Colin Bristow	Downgrade	Buy→Neutral	$38→$17
Mar 20, 2025	Guggenheim	Yatin Suneja	Maintained	Buy	—

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Immunovant, Raises Price Target to $50

JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the price target from $47 to $50.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Immunovant, Raises Price Target to $61

Citigroup analyst Samantha Semenkow maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $57 to $61.

Benzinga Newsdesk

CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts changed outlook on top names. Guggenheim raised price target for IMVT, Piper Sandler increased price target for TRV, and more.

Avi Kapoor

PRO
Guggenheim Maintains Buy on Immunovant, Raises Price Target to $62

Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $44 to $62.

Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Immunovant, Raises Price Target to $30

Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $23 to $30.

Benzinga Newsdesk

These Analysts Increase Their Forecasts On Immunovant After Q4 Results

Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&D expenses rose to $142.3 million. Analysts adjust price targets.

Avi Kapoor